Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial review 2022 priorities Financial performance Innovation: Pipeline overview Cardiovascular Immunology Neuroscience Ophthalmology Global Health Global Health Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 87 Investor Relations | Q3 2022 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation